Explore a selection of our essential drug information below, or:
Overview
- DrugBank ID
- DB04529
- Type
- Small Molecule
- Clinical Trials
- Phase 0
- 0
- Phase 1
- 0
- Phase 2
- 0
- Phase 3
- 0
- Phase 4
- 0
Identification
- Generic Name
- Desvancosaminyl vancomycin
- DrugBank Accession Number
- DB04529
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Desvancosaminyl vancomycin (DB04529)
- Weight
- Average: 1306.08
Monoisotopic: 1304.3355711 - Chemical Formula
- C59H62Cl2N8O22
- Synonyms
- Pseudovancomycin
- Vancomycin pseudoaglycone
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UDesvancosaminyl-vancomycin vancosaminetransferase Not Available Amycolatopsis orientalis UdTDP-epi-vancosaminyltransferase Not Available Amycolatopsis orientalis - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Oligopeptides
- Alternative Parents
- Cyclic peptides / Phenolic glycosides / Leucine and derivatives / N-acyl-alpha amino acids and derivatives / Hexoses / Alpha amino acid amides / Diarylethers / O-glycosyl compounds / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids show 21 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Acetal / Alcohol / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-oligopeptide / Amine / Amino acid / Amino acid or derivatives show 43 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- organochlorine compound, monosaccharide derivative, polyphenol, heterodetic cyclic peptide, cyclic ether, glycopeptide (CHEBI:47395)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 101485-50-1
- InChI Key
- QCHYVJAUGVHJHX-PZIRYZLHSA-N
- InChI
- InChI=1S/C59H62Cl2N8O22/c1-20(2)10-30(63-3)52(80)68-44-46(75)22-5-8-34(28(60)12-22)88-36-14-24-15-37(51(36)91-59-50(79)49(78)48(77)38(19-70)90-59)89-35-9-6-23(13-29(35)61)47(76)45-57(85)67-43(58(86)87)27-16-25(71)17-33(73)40(27)26-11-21(4-7-32(26)72)41(54(82)69-45)66-55(83)42(24)65-53(81)31(18-39(62)74)64-56(44)84/h4-9,11-17,20,30-31,38,41-50,59,63,70-73,75-79H,10,18-19H2,1-3H3,(H2,62,74)(H,64,84)(H,65,81)(H,66,83)(H,67,85)(H,68,80)(H,69,82)(H,86,87)/t30-,31+,38-,41-,42-,43+,44-,45+,46-,47-,48-,49+,50-,59+/m1/s1
- IUPAC Name
- (1S,2R,18R,19R,22S,25R,28R,40S)-22-(carbamoylmethyl)-5,47-dichloro-2,18,32,35,37-pentahydroxy-19-[(2R)-4-methyl-2-(methylamino)pentanamido]-20,23,26,42,44-pentaoxo-48-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2^{3,6}.2^{14,17}.1^{8,12}.1^{29,33}.0^{10,25}.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
- SMILES
- CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.226 mg/mL ALOGPS logP 1.6 ALOGPS logP -4 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 3.08 Chemaxon pKa (Strongest Basic) 8.89 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 21 Chemaxon Hydrogen Donor Count 18 Chemaxon Polar Surface Area 486.01 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 310.95 m3·mol-1 Chemaxon Polarizability 122.1 Å3 Chemaxon Number of Rings 9 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.6585 Blood Brain Barrier - 0.9912 Caco-2 permeable - 0.7221 P-glycoprotein substrate Substrate 0.8112 P-glycoprotein inhibitor I Non-inhibitor 0.8702 P-glycoprotein inhibitor II Non-inhibitor 0.9799 Renal organic cation transporter Non-inhibitor 0.9502 CYP450 2C9 substrate Non-substrate 0.842 CYP450 2D6 substrate Non-substrate 0.8321 CYP450 3A4 substrate Substrate 0.6331 CYP450 1A2 substrate Non-inhibitor 0.9005 CYP450 2C9 inhibitor Non-inhibitor 0.8935 CYP450 2D6 inhibitor Non-inhibitor 0.9168 CYP450 2C19 inhibitor Non-inhibitor 0.8863 CYP450 3A4 inhibitor Non-inhibitor 0.7683 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.827 Ames test Non AMES toxic 0.6584 Carcinogenicity Non-carcinogens 0.8953 Biodegradation Not ready biodegradable 0.9975 Rat acute toxicity 2.5447 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.997 hERG inhibition (predictor II) Non-inhibitor 0.7908
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Amycolatopsis orientalis
- Pharmacological action
- Unknown
- General Function
- Catalyzes the attachment of L-vancosamine to a monoglucosylated heptapeptide intermediate during the final stage of glycopeptide antibiotic vancomycin biosynthesis.
- Specific Function
- enzyme binding
- Gene Name
- gtfD
- Uniprot ID
- Q9AFC7
- Uniprot Name
- Desvancosaminyl-vancomycin vancosaminetransferase
- Molecular Weight
- 42880.545 Da
- Kind
- Protein
- Organism
- Amycolatopsis orientalis
- Pharmacological action
- Unknown
- General Function
- Catalyzes the attachment of 4-epi-vancosamine from a TDP donor to the beta-OH-Tyr-6 of the aglycone cosubstrate in the biosynthesis of glycopeptide antibiotic chloroeremomycin, a member of the vancomycin group of antibiotics. Strongly prefers devancoaminyl-vancomycin (DVV) as substrate rather than the heptapeptide vancomycin aglycone (AGV). Acts downstream of GtfB.
- Specific Function
- enzyme binding
- Gene Name
- gtfA
- Uniprot ID
- P96558
- Uniprot Name
- dTDP-epi-vancosaminyltransferase
- Molecular Weight
- 41661.965 Da
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52